Abstract
Seventy months after diagnosis, minimal residual disease is undetectable in a patient with Philadelphia chromosome-positive chronic myelogenous leukemia (CML) in long-lasting continuous cytogenetic conversion (CCC), achieved through alpha 2a-interferon (IFN-alpha) therapy. Fluctuating molecular remission, evaluated with the two-stage reverse transcriptase-polymerase chain reaction (RT-PCR) with nested primers, has persisted for two years at the maximum tolerable dose of IFN alpha (1.5 x 10(6) IU per day).
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Adult
-
Bone Marrow / pathology
-
Combined Modality Therapy
-
DNA, Neoplasm / genetics
-
Female
-
Fusion Proteins, bcr-abl / genetics
-
Humans
-
Hydroxyurea / therapeutic use
-
Immunologic Factors / therapeutic use*
-
Interferon alpha-2
-
Interferon-alpha / therapeutic use*
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / genetics
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / pathology
-
Leukemia, Myelogenous, Chronic, BCR-ABL Positive / therapy*
-
Polymerase Chain Reaction
-
Pregnancy
-
Pregnancy Complications, Neoplastic / therapy*
-
Recombinant Proteins
-
Remission Induction
Substances
-
DNA, Neoplasm
-
Immunologic Factors
-
Interferon alpha-2
-
Interferon-alpha
-
Recombinant Proteins
-
Fusion Proteins, bcr-abl
-
Hydroxyurea